Glad to share our recent paper in @eClinicalMed on the use of machine learning in predicting trajectories and outcomes in early-stage #masld secure-web.cisco.com/1MUeQWb…
1
64
Glad to share our latest work published in @JHepatology on #mechanotransduction and #NAFLD. The following link will allow anyone to have free access for the next few weeks: authors.elsevier.com/a/1fqhX…
3
Glad to see our provocative piece written with the great @jaumebosch9 on subclinical #portal hypertension in @JHepatology, promoting the paradigm that mechanosignaling pathways in #NAFLD link early increase in #sinusoidal pressure to #fibrosis authors.elsevier.com/a/1e6SO…
Just published a brief letter in @JHepatology arguing to keep #NAFLD as an acronym over #MAFLD as a newly proposed term. The new conceptual framework is great, but the familiar abbreviation could remain if 'nonalcoholic' becomes 'nutrition-associated'! authors.elsevier.com/a/1cTtv…
Thank you @AASLDtweets for a terrific #TLMdX that allowed so many friends, colleagues, and even #NobelPrize2020 laureates to bring the best and latest in our field straight to my living room during the past 4 days! @AASLDPresident @bezerratweet @MichiganLiver @raychungmd
Glad to share our recent OA review on #NAFLD and portal hypertension explorationpub.com/Journals/… describing EUS-guided measurement of the portal pressure gradient and set to change the perception that PPG is not a major player until it is high enough to call "clinically significant"
Gyorgy Baffy retweeted
Replying to @HollyJGreen
I guess a truly international palindrome will never happen again as long as there are some *crazy* languages such as Hungarian in which the date begins with the year (2020.02.02). Fortuitously, however, the Hungarian version happens to be just another palindrome! @HollyJGreen
Retirement dinner honoring Raj Goyal to mark an era of renowned clinical research and outstanding patient care at @VABostonHC as we all continue to look for guidance and wisdom from this humble giant and pioneer of gastrointestinal physiology. @AmerGastroAssn @AGA_Gastro
5
Gyorgy Baffy retweeted
Interim regenerate phase 3 (OCA) results are published. No efficacy on NASH endpoint. A signal on fibrosis with only 25mg, but can’t ignore 50% who get pruritus and 9% drop out. Really need to know predictors of response #Nash @IanARowe @phil_newsome7 @drrichardparker
Leon Schiff state-of-the-art lecture by Dr Josip Llovet @MountSinaiNYC and @BCLC_group on molecular pathogenesis and management of #HCC @AASLDtweets #LiverMtg19
#FMT affects brain inflammation and glia activation: @JasmohanBajaj transplanted stools of HE patients into germ-free mice and found higher frontal cortex markers IBA-1, IL1beta and MCP-1 if FMT done before abx Rx. Stool supernatant had no effect. @AASLDtweets #LiverMtg19
Is there a universal biomarker panel to predict #cirrhosis in #NAFLD? Dr TG Oh @salkinstitute @UCSDHealth reports on combined signatures of 19 gut microbiota species and 17 novel microbial metabolites such as kynurenic acid, enterolactone and vit D3 @AASLDtweets #LiverMtg2019
1
Caveat added by @JasmohanBajaj to biomarker study @salkinstitute @UCSDHealth: Do not compare apple to oranges and lump comp/decomp cirrhosis cohorts, but also look at patients to judge their advanced status rather than at their #microbiome @AASLDtweets #LiverMtg19
Saroglitazar effects in 106 noncirrhotic #NAFLD cases, reported by Dr Gawrieh @IUHepatology. Primary endpoint ALT drop at 16wks met at all doses with 44% peak reduction. HOMA-IR (but not A1c), TG, HDL, PDFF and ELF impact only significant at 4mg. @AASLDtweets #LiverMtg19
Innovative therapy for #alcoholic hepatitis? Dr Hassanein from Southern California GI and Liver Centers on early results with the sulfated oxysterol DUR-928, a cytotoxic molecule with gene regulatory properties and antifibrotic effects @AASLDtweets #LiverMtg19
DUR-928 was tolerated at 30, 90, and 150mg parenteral doses in #alcoholic hepatitis patients with overall DF ~53 and responding with average <0.19 Lille scores and ~5 MELD drop @AASLDtweets #LiverMtg19
LIFT-HDV phase 2a study report on using lonafarnib, ritonavir and PEF-IFN lambda for 24 weeks in delta hepatitis by Dr Christopher Koh. Primary endpoint >2log #HDV RNA decline from 4.74 baseline average was met with 3.18 log drop at 24wks @NIH @NIDDKgov @AASLDtweets #LiverMtg19
Licogliflozin improved A1c and liver PDFF in #NAFLD with both 30 and 150mg dosing at 12 weeks with mixed and mild effect of fibrosis markers as reported by Dr Stephen Harrison @AASLDtweets #LiverMtg19
Same place, (almost) same time: Liver Meeting 2020 back to Boston #LiverMtg19 @AASLDtweets
Wrapping up #LiverMg19 with new promises: Late-breaking abstract session begins with interim analysis of phase 2a LIK066X2204, licogliflozin 30 vs 150mg in bx-proven or diabetic #NAFLD. ALT decrease is only primary endpoint, met with higher dose after 12 @AASLDtweets
















